US4985253A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Sustained release composition for pharmaceutical substances comprising a silicone elastomer carrier
Assignee: Sumitomo Pharma Co Ltd
•
Filing: 1990-02-16
•
Granted: 1991-01-15
•
Expires: 2010-02-16
Abstract
Abstract A sustained release composition applicable for human beings and mammals which comprises (a) a silicone elastomer and (b) a pharmaceutical substance optionally with (c) albumin. When the pharmaceutical substance is of high molecular weight, and can exert its pharmaceutical effect in a trace amount, its continuous release over a long period is attained by application of this invention.
Inventors
- 👤 Keiji Fujioka
- 👤 Shigeji Sato
- 👤 Nobuhiko Tamura
- 👤 Yoshihiro Takada
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 23:57
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2031; A61K9/2036; A61K9/0012; A61K9/0019; A61K9/0024
Claims Analysis
Total Claims: 30
Claim 1
Independent Claim
42 words
A sustained release composition comprising a silicone elastomer matrix, a pharmaceutical substance uniformly mixed in said matrix and albumin to provide sustained release of said pharmaceutical substance from said silicone elastomer matrix and stabilize said pharmaceutical substance in said silicone elastomer matrix.
Claim 2
Dependent Claim
42 words
A sustained release composition comprising a silicone elastomer matrix, a pharmaceutical substance uniformly mixed in said matrix and albumin to provide sustained release of said pharmaceutical substance from said silicone elastomer matrix and stabilize said pharmaceutical substance in said silicone elastomer matrix.
Claim 3
Dependent Claim
41 words
A sustained release composition comprising a silicone elastomer matrix, a pharmaceutical substance dispersed in said matrix and albumin to provide sustained release of said pharmaceutical substance from said silicone elastomer matrix and stabilize said pharmaceutical substance in said silicone elastomer matrix.
Claim 4
Dependent Claim
41 words
A sustained release composition comprising a silicone elastomer matrix, a pharmaceutical substance dispersed in said matrix and albumin to provide sustained release of said pharmaceutical substance from said silicone elastomer matrix and stabilize said pharmaceutical substance in said silicone elastomer matrix.
Claim 5
Dependent Claim
24 words
A sustained release composition comprising a hollow vessel of a silicone elastomer matrix, having a pharmaceutical substance and albumin contained within said hollow vessel.
Claim 6
Dependent Claim
24 words
A sustained release composition comprising a hollow vessel of a silicone elastomer matrix, having a pharmaceutical substance and albumin contained within said hollow vessel.
Claim 7
Dependent Claim
61 words
A sustained release composition comprising a silicone elastomer matrix, a pharmaceutical substance dispersed in said matrix in an amount of from 1 to 20% by weight and albumin in an amount of from 20 to 30% by weight to provide sustained release of said pharmaceutical substance from said silicone elastomer matrix and stabilize said pharmaceutical substance in said silicone elastomer matrix.
Claim 8
Dependent Claim
61 words
A sustained release composition comprising a silicone elastomer matrix, a pharmaceutical substance dispersed in said matrix in an amount of from 1 to 20% by weight and albumin in an amount of from 20 to 30% by weight to provide sustained release of said pharmaceutical substance from said silicone elastomer matrix and stabilize said pharmaceutical substance in said silicone elastomer matrix.
Claim 9
Independent Claim
54 words
A method for enhancing the amount or concentration of a pharmaceutical substance as released from a sustained release composition comprising uniformly mixing a pharmaceutical substance with a silicone elastomer and albumin to provide sustained release of said pharmaceutical substance from said silicone elastomer matrix and stabilize said pharmaceutical substance in said silicone elastomer matrix.
Claim 10
Independent Claim
54 words
A method for enhancing the amount or concentration of a pharmaceutical substance as released from a sustained release composition comprising uniformly mixing a pharmaceutical substance with a silicone elastomer and albumin to provide sustained release of said pharmaceutical substance from said silicone elastomer matrix and stabilize said pharmaceutical substance in said silicone elastomer matrix.
Claim 11
Dependent Claim
37 words
A method according to claim 5, wherein said pharmaceutical substance is mixed in an amount of from 1 to 20% by weight and said albumin is mixed in an amount of from 20 to 30% by weight.
Claim 12
Dependent Claim
37 words
A sustained release composition comprising a silicone elastomer matrix, a pharmaceutical substance and albumin to provide sustained release of said pharmaceutical substance from said silicon elastomer matrix and stabilize said pharmaceutical substance in said silicon elastomer matrix.
Claim 13
Dependent Claim
37 words
A sustained release composition comprising a silicone elastomer matrix, a pharmaceutical substance and albumin to provide sustained release of said pharmaceutical substance from said silicon elastomer matrix and stabilize said pharmaceutical substance in said silicon elastomer matrix.
Claim 14
Dependent Claim
22 words
The composition according to claim 1, wherein the pharmaceutical substance is contained in a context of not more than 15% by weight.
Claim 15
Dependent Claim
13 words
The composition according to claim 1 or 2, which is an injectable composition.
Claim 16
Dependent Claim
16 words
The composition according to claim 9, which is molded in a cylindrical, needle or tube shape.
Claim 17
Dependent Claim
27 words
The composition according to claim 10, which is shaped in a diameter of not more than 4 mm and a length of not more than 50 mm.
Claim 18
Dependent Claim
20 words
The composition according to claim 1 or 2, wherein the pharmaceutical substance has a molecular weight of 1,000 to 500,000.
Claim 19
Dependent Claim
29 words
The composition according to claim 1 or 2 wherein the pharmaceutical substance is one desired to be administered in a trace amount continuously over a long period of time.
Claim 20
Dependent Claim
38 words
The composition according to any of claims 1 to 3, wherein the pharmaceutical substance is a substance having growth regulating activity, a substance having bone metabolizing activity, a substance having thrombolytic activity or a substance having immumoregulating activity.
Claim 21
Dependent Claim
20 words
The composition according to any of claims 1 to 34, wherein the pharmaceutical substance is a substance having anti-inflammatory activity.
Claim 22
Dependent Claim
30 words
The composition according to any of claims 1 to 3, wherein the pharmaceutical substance is continuously released over a long period of time from the silicone elastomer as the matrix.
Claim 23
Dependent Claim
45 words
The composition according to any of claims 1 to 3, wherein the pharmaceutical substance is contained within a hollow vessel comprised of said silicone elastomer, whereby said pharmaceutical substance is continuously released over a long period of time through the wall of said hollow vessel.
Claim 24
Dependent Claim
24 words
The composition according to claim 1 or 2, wherein the pharmaceutical substance is contained in a content of not more than 50% by weight.
Claim 25
Dependent Claim
23 words
The composition according to claim 1 or 2, wherein the albumin is contained in a content of not more than 50% by weight.
Claim 26
Dependent Claim
39 words
The composition according to claim 1 or 2, wherein the pharmaceutical substance is contained in a content of not more than 50% by weight and the albumin is contained in a content of not more than 50% by weight.
Claim 27
Dependent Claim
23 words
The composition according to claim 14, wherein the pharmaceutical substance having growth regulating activity is growth hormone, growth hormone releasing factor or somatomedin.
Claim 28
Dependent Claim
16 words
The composition according to claim 14, wherein the pharmaceutical substance having bone metabolizing activity is calcitonin.
Claim 29
Dependent Claim
17 words
The composition according to claim 14, wherein the pharmaceutical substance having thrombolytic activity is tissue plasminogen activator.
Claim 30
Dependent Claim
27 words
The composition according to claim 14, wherein the pharmaceutical substance having immunoregulating activity is interferon, interleukin, colony stimulating factor, macrophage activating factor or macrophage migration inhibitory factor.
References Cited (Backward Citations)
US3279996A
Cited
US3545439A
Cited
US4464468A
Cited
US4004979A
Cited
US4230686A
Cited
US4012497A
Cited
US4053580A
Cited
US4164560A
Cited
US4391797A
Cited
US4275000A
Cited
GB2021412A
Cited
US4191741A
Cited
US4376765A
Cited
US4357312A
Cited
US4478596A
Cited
US4613330A
Cited
US4452775A
Cited
EP0139286A2
Cited
EP0152736A2
Cited
US4591496A
Cited
US4559054A
Cited
US4650772A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-01-14 | 1994-07-16 | 1995-01-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-01-14 | 1998-07-16 | 1999-01-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-01-14 | 2002-07-16 | 2003-01-15 | $7700.00 | Window Closed / Lapsed |